On June 22, 2026, InterCure Ltd. entered into a binding term sheet for a private placement securing approximately NIS 22 million (US$7 million) in investment commitments. The company will issue approximately 7.9 million units, each comprising one ordinary share and one warrant exercisable for five years at NIS 4.125 per share. Completion depends on definitive agreements and customary closing conditions; shareholder approval is required only for the participation of CEO and director Alexander Rabinovich. InterCure is a medical device company that develops and commercializes surgical solutions for the treatment of benign prostatic hyperplasia.
